Indegene Limited — Capital/Financing Update 2025

Feb 6, 2025

INDGN/SE/2024-25/99

==> picture [78 x 76] intentionally omitted <==

February 06, 2025

BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN

Dear Sir / Madam,

Sub: Indegene Expands Footprint in Europe, Launches New Entity in Spain

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is a press release dated February 06, 2025, titled ‘Indegene Expands Footprint in Europe, Launches New Entity in Spain’.

The above information will be made available on the website of the Company: https://www.indegene.com/

A copy of the Press Release is enclosed for your reference.

This is for your information and records.

For Indegene Limited

Srishti Digitally signed by Ramesh Srishti Ramesh Kaushik Date: 2025.02.06 Kaushik 11:56:58 +05'30'

Srishti Ramesh Kaushik Company Secretary and Compliance officer

==> picture [141 x 29] intentionally omitted <==

Indegene Limited (Formerly Indegene Private Limited), Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777 www.indegene.com

CIN: U73100KA1998PLC102040

==> picture [64 x 64] intentionally omitted <==

Press Release

Indegene Expands Footprint in Europe, Launches New Entity in Spain

Madrid, Spain and Bengaluru, India, February 6, 2025: Indegene, a digital-first life sciences commercialization company, today announced the launch of a new entity in Spain. This move marks a key step in the company’s ongoing strategic expansion in Europe and aligns with Indegene’s commitment to helping life sciences companies accelerate AI-driven innovation and make their operations future-ready.

Indegene’s new Spain entity will serve as a key delivery hub for its Europe-based clients, helping them drive hyper-personalization and significantly elevate HCP and patient experience. The company is strengthening its already existing employee base in Spain, with capabilities in medical affairs, data and analytics, creative design, engineering, digital marketing and customer experience.

“Growing R&D investments, a thriving life sciences innovation ecosystem and a high-quality talent pool make Spain a vital market and talent hub for life sciences companies in Europe”, said Manish Gupta, Chairman and CEO, Indegene. “With our new entity in Spain, we can co-innovate and collaborate much better with clients, helping them use data and AI more effectively to modernize commercialization processes and fast-track business transformation.”

Indegene already has a significant presence in Europe, with centers in the UK, Germany, Ireland and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. Indegene supports many leading life sciences clients in the region in various ways across the commercialization value chain.

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. It is one of the very few companies globally where a medical doctor and a data scientist work next to each other to solve big, impactful problems in life sciences. More than 20% of Indegene’s employees come from a medical education background and they work very closely with about 600 technologists, collaborating on advanced artificial intelligence (AI), machine learning (ML) and other technologies.

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies, many emerging biotech firms, and medical device companies. With over 5,000 employees worldwide, Indegene’s vast global footprint underscores its ability to scale and meet the evolving needs of the world’s leading pharma organizations across markets.

About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives Indegene’s team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

For media inquiries, please contact: Yadunandan K V | yadunandan.kv@indegene.com